Table 3.
The relationship between mGPS and clinicopathological/PET-CT characteristics in patients with lung cancer.
| Characteristics | mGPS 0 (n = 58) | mGPS 1 (n = 20) | mGPS 2 (n = 41) | p-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 36 (62.1) | 7 (35.0) | 14 (34.1) | 0.617 |
| Female | 22 (37.9) | 13 (65.0) | 27 (65.9) | |
| Age | ||||
| < 65 | 10 (17.2) | 4 (20.0) | 3 (7.3) | 0.011 |
| 65–74 | 25 (43.1) | 9 (45.0) | 20 (48.8) | |
| > 75 | 23 (39.7) | 7 (35.0) | 18 (43.9) | |
| TNM | ||||
| I | 23 (39.7) | 8 (40.0) | 11 (26.8) | 0.695 |
| II | 11 (19.0) | 3 (15.0) | 8 (19.5) | |
| III | 24 (41.4) | 9 (45.0) | 22 (53.7) | |
| ECOG-PS | ||||
| 0/1 | 32 (55.2) | 13 (65.0) | 23 (56.1) | 0.735 |
| ≥ 2 | 26 (44.8) | 7 (35.0) | 18 (43.9) | |
| Inflammatory response | ||||
| NLR | ||||
| < 3 | 35 (60.3) | 6 (30.0) | 12 (29.3) | 0.002 |
| 3–5 | 17 (29.3) | 6 (30.0) | 12 (29.3) | |
| > 5 | 6 (10.3) | 8 (40.0) | 17 (41.5) | |
| MUST | ||||
| Low risk | 30 (51.7) | 11 (55.0) | 10 (24.4) | 0.007 |
| Intermediate risk | 25 (43.1) | 7 (35.0) | 20 (48.8) | |
| High risk | 3 (5.2) | 2 (10.0) | 11 (26.8) | |
| Body composition | ||||
| BMI kg/m2 | ||||
| < 25 | 25 (43.1) | 8 (40.0) | 23 (56.1) | 0.348 |
| ≥ 25 | 33 (56.9) | 12 (60.0) | 18 (43.9) | |
| Visceral obesity | ||||
| VFA | 122.56 (21.73–549.90) | 140.19 (46.71–577.08) | 148.45 (14.35–433.30) | 0.770 |
| Visceral obesity | ||||
| No | 19 (32.8) | 7 (35.0) | 19 (46.3) | 0.374 |
| Yes | 39 (67.2) | 13 (65.0) | 22 (53.7) | |
| SMI | 43.87 (29.40–72.04) | 43.80 (29.43–74.36) | 44.66 (34.70–73.49) | 0.675 |
| Low SMI | ||||
| No | 29 (50.0) | 11 (55.0) | 21 (51.2) | 0.928 |
| Yes | 29 (50.0) | 9 (45.0) | 20 (48.8) | |
| SMD | 33.23 (13.98–51.24) | 36.65 (9.58–49.96) | 35.18 (16.81–49.25) | 0.312 |
| Low SMD | ||||
| No | 18 (31.0) | 9 (45.0) | 18 (43.9) | 0.330 |
| Yes | 40 (69.0) | 11 (55.0) | 23 (56.1) | |
| PET-CT analysis | ||||
| TLG | 64.01 (3.47–912.18) | 115.77 (5.15–968.76) | 227.40 (10.82–2070.90) | < 0.001 |
| TLG > 68.89 | ||||
| No | 31 (53.4) | 7 (35.0) | 9 (22.0) | 0.006 |
| Yes | 27 (46.6) | 13 (65.0) | 32 (78.0) | |
| Survival | ||||
| Survival rate (3 year) | ||||
| No | 37 (63.8) | 16 (80.0) | 31 (75.6) | 0.267 |
| Yes | 21 (36.2) | 4 (20.0) | 10 (24.4) | |
TNM Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group Performance Status, mGPS modified Glasgow Prognostic Score, NLR Neutrophil Lymphocyte Ratio, MUST Malnutrition Universal Screening Tool, BMI Body Mass Index, VFA Visceral Fat Area, SMI Skeletal Muscle Index, SMD Skeletal Muscle Density, TLG Total Lesion Glycolysis.